Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100971 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia
A Phase 1 study, sponsored by Boston Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00100971 is a Phase 1 study that was terminated before completion, run by Boston Medical Center. The registered enrollment target is 9 participants.
The verdict
NCT00100971, a Phase 1 study, was terminated before completion, sponsored by Boston Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's white blood cells and cancer cells may make the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with acute myeloid leukemia.
Interventions
- DRUG autologous tumor cell vaccine
- DRUG therapeutic autologous dendritic cells
- PROCEDURE tumor cell-derivative vaccine therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00100971
The ClinicalTrials.gov registry entry for NCT00100971 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which autologous tumor cell vaccine is the first listed.
NCT00100971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00100971 about?
NCT00100971 is a clinical study titled "Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia". RATIONALE: Vaccines made from a person's white blood cells and cancer cells may make the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with acute myeloid leukemia.
What is the current status of trial NCT00100971?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2004-04. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00100971?
The interventions under investigation include: autologous tumor cell vaccine (DRUG), therapeutic autologous dendritic cells (DRUG), tumor cell-derivative vaccine therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00100971?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.